TRANSCODE THERAPEUTICS, INC.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering

Partnering

Partnering with TransCode

If you share our vision and passion for transforming cancer treatment, reach out. ​
  • Immunotherapy - Checkpoint Inhibitors (targeting PDL1/PD-1); Pattern Recognition Receptors - targeting RIG-I gene for innate immunity
  • Gene-Editing - proprietary delivery of ribonucleoproteins
  • Radiotherapy - as therapies or diagnostics
  • Cancer Vaccines - employing delivery of mRNA to tumors
  • Diagnostics - assessing biomarkers as diagnostic aides to earlier detection, monitoring success of therapy during treatment and monitoring success post treatment
  • Other targeted therapies - including peptide, protein, or small molecule-based approaches.

Email: [email protected]
Picture
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

Mission
clinical trials
careers

​

About

​METASTATIC DISEASE
TTX-MC138
​SCIENCE
​PIPELINE
​DELIVERY PLATFORM
​OTHER PRODUCTS
​LEADERSHIP


Publications

​PUBLICATIONS

Partnering

partnering

Contact/Support

CONTACT
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2025.​ ALL RIGHTS RESERVED.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering